NIH totals $85M for BRAIN initiative in 2015
The National Institutes of Health has shared its second wave of grants to support the goals of the Brain Research through…
Pharmaceuticals, Biotechnology and Life Sciences
The National Institutes of Health has shared its second wave of grants to support the goals of the Brain Research through…
Allergan has completed the acquisition of Kythera Biopharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel…
Allergan plc has announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market Juvederm ultra XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21.
Teva Pharmaceutical Industries Ltd., has announced that Lancet Neurology published online, as back-to-back articles, the results from two Phase 2b…
Novartis announced on Wednesday that results from the pivotal Phase III FUTURE 1 study for Secukinumab in psoriatic arthritis (PsA)…
Sanofi announced on Tuesday that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for lixisenatide.
ImmuPharma PLC the specialist drug discovery and development company, has announced the appointment of Tim McCarthy as Non-executive Chairman, with immediate effect.
Veidekke’s Danish subsidiary Hoffmann has been awarded a contract to build a new national research and treatment centre for particle therapy in Aarhus in Jutland.
Meiji Seika Pharma Co., Ltd. announced on Tuesday that the U.S. Food and Drug Administration (FDA) has designated the Company’s lead antibiotic product, ME1100 (arbekacin inhalation solution), as a Qualified Infectious Disease Product (QIDP) for the adjunctive treatment of mechanically ventilated patients with bacterial pneumonia.